Through this optimisation, they developed SIAIS178 (Figure 3), leading to effective BCR-ABL degradation (DC50 = 8.5 nM) with significant growth inhibition in BCR-ABL-positive leukemic cells (IC50 = 24.0 nM; for dasatinib: IC50 = 0.9 nM; for DAS-6–2-2–6-CRBN: 3.4 nM) in vitro and tumour regression in K562 xenograft models in vivo. Here, BCR is linked to neoplasm.